Sign In
Buy NKTR
$72.76
+2.17 (+3.07%)
At Close: Aug 04, 2026
Nektar Sends Shot Across Bristol Myers Squibb's Bow With Big Pfizer Collaboration
08:11am, Thursday, 23'rd Sep 2021
The collaboration is a clear message sent from Nektar CEO Howard Robin that any acquisition has to fairly value Nektar's ENTIRE portfolio. Pfizer may have bigger plans in store for Nektar.
Nektar (NKTR) Signs Deals With Pfizer, Merck KGaA for NKTR-255
12:16pm, Wednesday, 22'nd Sep 2021
Nektar (NKTR) signs a collaboration deal with Pfizer and Merck KGaA to develop a combination of its NKTR-255 with the latter's Bavencio for treating urothelial carcinoma.
Nektar, Merck Germany, Pfizer Join Forces For Mid-Stage Bladder Cancer Study
11:02am, Tuesday, 21'st Sep 2021
Nektar Therapeutics Inc (NASDAQ: NKTR) has entered into a new oncology clinical collaboration with Merck KGaA (OTC: MKGAF) and Pfizer Inc (NYSE: PFE) to evaluate the maintenance regimen of NKTR
SAN FRANCISCO, Sept. 21, 2021 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) announced it has entered into a new oncology clinical collaboration with Merck KGaA, Darmstadt, Germany and Pfizer Inc.
Nektar And Bristol Myers Squibb Expecting Bempeg Approval
08:00am, Saturday, 18'th Sep 2021
All signs point to approval of Bempeg, Nektar's flagship anti-cancer compound. Retail investors are still caught in the web of lies propagated by Short & Distort operators.
Nektar Therapeutics Stock Performance In The Pandemic vs 2008
08:30am, Thursday, 09'th Sep 2021
We believe that Nektar Therapeutics stock, a biopharmaceutical company focused on discovering and developing medicines in areas that include cancer, autoimmune disease, and chronic pain, is a good buy
Mr. Manipulation Meets Ms. Opportunity At The Nektar Cocktail Party
10:37am, Friday, 27'th Aug 2021
Mr. Manipulation Meets Ms. Opportunity At The Nektar Cocktail Party
SAN FRANCISCO, July 27, 2021 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter 2021 on Thursday, August 5, 2021, after the close of U.S.
Nektar Appoints Dimitry S.A. Nuyten, M.D.
09:00am, Monday, 19'th Jul 2021
SAN FRANCISCO, July 19, 2021 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) announced today that it has appointed Dimitry S.A. Nuyten, M.D.
Nektar In Renal Cell Carcinoma: An Overview
08:18am, Saturday, 10'th Jul 2021
Nektar is developing Bempeg+Opdivo in advanced or metastatic RCC. The company is cash rich and pipeline heavy.
Nektar Therapeutics to Participate in Fireside Chat at the Goldman Sachs 42nd Annual Global Healthcare Conference
08:30am, Monday, 07'th Jun 2021
SAN FRANCISCO, June 7, 2021 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR) senior management is scheduled to participate in a virtual fireside chat at the upcoming Goldman Sachs 42nd Annual Globa
SAN FRANCISCO, May 20, 2021 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced the publication of preclinical data in the Journal of Translational Autoimmunity describing NKTR-358, a
SAN FRANCISCO, May 18, 2021 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced the publication of preclinical data from its second major immuno-oncology cytokine program, NKTR-255, i
Nektar (NKTR) Moves 8.5% Higher: Will This Strength Last?
03:46am, Monday, 10'th May 2021
Nektar (NKTR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Nektar Therapeutics (NKTR) CEO Howard Robin on Q1 2021 Results - Earnings Call Transcript
12:48pm, Friday, 07'th May 2021
Nektar Therapeutics (NKTR) CEO Howard Robin on Q1 2021 Results - Earnings Call Transcript
